Jump to content

Bucindolol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 02:07, 22 December 2020 (Task 18 (cosmetic): eval 3 templates: del empty params (6×);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Bucindolol
Clinical data
ATC code
  • none
Identifiers
  • 2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethyl-ethyl]amino]propoxy]benzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.114.291 Edit this at Wikidata
Chemical and physical data
FormulaC22H25N3O2
Molar mass363.461 g·mol−1
3D model (JSmol)
  • N#Cc0ccccc0OCC(O)CNC(C)(C)Cc1c[nH]c2c1cccc2

Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity.[1][2] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.[1][3]

See also

References

  1. ^ a b "formularyjournal.modernmedicine.com". Archived from the original on 2012-03-04.
  2. ^ Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology. 56 (1): 30–6. doi:10.1159/000028179. PMID 9467185.
  3. ^ "FDA rejects bucindolol and questions trial integrity « CardioBrief".


Stub icon

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Bucindolol&oldid=995631734"